Ahmad Z Al Meslamani (Ahmad Z AlMeslamani)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 80

Top Venues

Journal of medical economics

Expert opinion on biological therapy

Expert opinion on drug safety

Expert review of anti-infective therapy

University of Petra (MSC)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Petra Sep 03 2017 - Jul 07 2019

Jordan

MSC :: Department of Pharmacology and Biomedical Sciences

Philadelphia University Sep 13 2013 - Jul 01 2017

Jordan

BSC :: Pharmacy

Publications

Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Bridging the gap: The future of biosimilars regulations. Human vaccines & immunotherapeutics 20 (1) (2024)
Ahmad Z Al Meslamani
Challenges in health economics research: insights from real-world examples. Journal of medical economics 27 (1) (2024)
Ahmad Z Al Meslamani
Beyond resistance: assessing sulbactam-Durlobactam's role in Today's clinical landscape. Expert review of anti-infective therapy (2024)
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety. Expert opinion on biological therapy (2024)
Ahmad Z Al Meslamani
Why are outcome-based drug safety research studies scarce? Insights into operational challenges and potential solutions. Expert opinion on drug safety (2024)
Ahmad Z Al Meslamani, Eman Merghani Ali
Navigating the crossroads: asthma, trained immunity, and infection susceptibility. Expert review of clinical immunology (2024)
Ahmad Z Al Meslamani
Adverse Drug Event Reporting Among Women: Uncovering Disparities in Underserved Communities. Expert opinion on drug safety (2024)
Ahmad Z Al Meslamani, Eman Merghani Ali
Navigating the crossroads: asthma, trained immunity, and infection susceptibility. Expert review of clinical immunology 20 (9) (2024)
Ahmad Z Al Meslamani
Antiretroviral therapy response: exploring the potential influence of SARS-CoV-2. Expert review of clinical pharmacology 17 (7) (2024)
Abdallah Abou Hajal, Ahmad Z Al Meslamani
Insights into artificial intelligence utilisation in drug discovery. Journal of medical economics 27 (1) (2024)
Ahmad Z Al Meslamani, Derar H Abdel-Qader, Amira B Kassem, Nadia Al Mazrouei
Disparities in drug safety practices in developing nations: focusing on underlying factors and implications for global health. Expert opinion on drug safety 23 (4) (2024)
Ahmad Z Al Meslamani
Challenges in health economics research: insights from real-world examples. Journal of medical economics 27 (1) (2024)
Ahmad Z Al Meslamani
Why are digital health policies crucial? Journal of medical economics 27 (1) (2024)
Ahmad Z Al Meslamani
Antiretroviral therapy response: exploring the potential influence of SARS-CoV-2. Expert review of clinical pharmacology (2024)
Ahmad Z Al Meslamani, Eman Merghani Ali
Navigating the crossroads: asthma, trained immunity, and infection susceptibility. Expert review of clinical immunology 20 (9) (2024)
Ahmad Z Al Meslamani
Adverse drug event reporting among women: uncovering disparities in underserved communities. Expert opinion on drug safety 23 (5) (2024)
Ahmad Z Al Meslamani
Why are outcome-based drug safety research studies scarce? Insights into operational challenges and potential solutions. Expert opinion on drug safety 23 (2) (2024)
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Bridging the gap: The future of biosimilars regulations. Human vaccines & immunotherapeutics 20 (1) (2024)
Ahmad Z Al Meslamani
Decoding treatment efficacy: uncovering response and failure dynamics to biologics in asthma. Expert opinion on biological therapy 24 (1-2) (2024)
Abdallah Abou Hajal, Ahmad Z Al Meslamani
Insights into artificial intelligence utilisation in drug discovery. Journal of medical economics 27 (1) (2024)
Ahmad Z Al Meslamani
Beyond resistance: assessing sulbactam-durlobactam's role in today's clinical landscape. Expert review of anti-infective therapy (2024)
Ahmad Z Al Meslamani
Why are outcome-based drug safety research studies scarce? Insights into operational challenges and potential solutions. Expert opinion on drug safety 23 (2) (2024)
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety. Expert opinion on biological therapy 24 (7) (2024)
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Barriers to transforming community pharmacies into point-of-care testing sites in low- and middle-income countries. The International journal of pharmacy practice (2024)
Ahmad Z Al Meslamani
Decoding treatment efficacy: uncovering response and failure dynamics to biologics in asthma. Expert opinion on biological therapy (2024)
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Barriers to transforming community pharmacies into point-of-care testing sites in low- and middle-income countries. The International journal of pharmacy practice 32 (3) (2024)
Ahmad Z Al Meslamani
Why are outcome-based drug safety research studies scarce? Insights into operational challenges and potential solutions. Expert opinion on drug safety (2024)
Ahmad Z Al Meslamani
Antiretroviral therapy response: exploring the potential influence of SARS-CoV-2. Expert review of clinical pharmacology (2024)
Ahmad Z Al Meslamani
Decoding treatment efficacy: uncovering response and failure dynamics to biologics in asthma. Expert opinion on biological therapy 24 (1-2) (2024)
Ahmad Z Al Meslamani
Adverse drug event reporting among women: uncovering disparities in underserved communities. Expert opinion on drug safety (2024)
Ahmad Z Al Meslamani
Why are outcome-based drug safety research studies scarce? Insights into operational challenges and potential solutions. Expert opinion on drug safety 23 (2) (2024)
Ahmad Z Al Meslamani
Is the world crippled by antimicrobial resistance, or simply lacking information? Expert review of anti-infective therapy (2024)
Ahmad Z Al Meslamani
Short and long-term economic implications of biosimilars. Expert opinion on biological therapy 24 (7) (2024)
Ahmad Z Al Meslamani
Why are outcome-based drug safety research studies scarce? Insights into operational challenges and potential solutions. Expert opinion on drug safety 23 (2) (2024)
Ahmad Z Al Meslamani
Challenges in health economics research: insights from real-world examples. Journal of medical economics (2024)
Ahmad Z Al Meslamani
Is the world crippled by antimicrobial resistance, or simply lacking information? Expert review of anti-infective therapy 22 (6) (2024)
Ahmad Z Al Meslamani, Derar H Abdel-Qader, Amira B Kassem, Nadia Al Mazrouei
Disparities in Drug Safety Practices in Developing Nations: focusing on underlying factors and implications for global health. Expert opinion on drug safety (2024)
Ahmad Z Al Meslamani
Short and long-term economic implications of biosimilars. Expert opinion on biological therapy 24 (7) (2024)
Ahmad Z Al Meslamani, Eman Merghani Ali
Navigating the crossroads: asthma, trained immunity, and infection susceptibility. Expert review of clinical immunology (2024)
Ahmad Z Al Meslamani
Short and long-term economic implications of biosimilars. Expert opinion on biological therapy (2024)
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety. Expert opinion on biological therapy 24 (7) (2024)
Ahmad Z Al Meslamani
Understanding patient variability to biologic treatments in inflammatory bowel disease. Expert opinion on biological therapy 24 (5) (2024)
Ahmad Z Al Meslamani
Why Are Digital Health Policies Crucial? Journal of medical economics (2024)
Ahmad Z Al Meslamani, Derar H Abdel-Qader, Amira B Kassem, Nadia Al Mazrouei
Disparities in drug safety practices in developing nations: focusing on underlying factors and implications for global health. Expert opinion on drug safety 23 (4) (2024)
Ahmad Z Al Meslamani
Short and long-term economic implications of biosimilars. Expert opinion on biological therapy (2024)
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety. Expert opinion on biological therapy 24 (7) (2024)
Anan S Jarab, Shrouq R Abu Heshmeh, Ahmad Z Al Meslamani
Bridging the gap: The future of biosimilars regulations. Human vaccines & immunotherapeutics 20 (1) (2024)
Ahmad Z Al Meslamani
Decoding treatment efficacy: uncovering response and failure dynamics to biologics in asthma. Expert opinion on biological therapy (2024)
Ahmad Z Al Meslamani
Why are digital health policies crucial? Journal of medical economics 27 (1) (2024)
Ahmad Z Al Meslamani, Derar H Abdel-Qader, Amira B Kassem, Nadia Al Mazrouei
Disparities in drug safety practices in developing nations: focusing on underlying factors and implications for global health. Expert opinion on drug safety (2024)
Ahmad Z Al Meslamani
Understanding patient variability to biologic treatments in inflammatory bowel disease. Expert opinion on biological therapy (2024)
Ahmad Z Al Meslamani
Short and long-term economic implications of biosimilars. Expert opinion on biological therapy 24 (7) (2024)
Ahmad Z Al Meslamani
Is the world crippled by antimicrobial resistance, or simply lacking information? Expert review of anti-infective therapy 22 (6) (2024)
Ahmad Z Al Meslamani
How climate change influences pathogen transmission. Pathogens and global health (2023)
Ahmad Z Al Meslamani
Applications of AI in pharmacy practice: a look at hospital and community settings. Journal of medical economics (2023)
Ahmad Z Al Meslamani, Anan S Jarab, Mohammad A Ghattas
The role of machine learning in healthcare responses to pandemics: maximizing benefits and filling gaps. Journal of medical economics (2023)
Ahmad Z Al Meslamani
Gaps in digital health policies: an insight into the current landscape. Journal of medical economics (2023)
Ahmad Z Al Meslamani
Technical and regulatory challenges of digital health implementation in developing countries. Journal of medical economics (2023)
Ahmad Z Al Meslamani
Insights into the immunological links between dietary habits and asthma. Expert review of clinical immunology (2023)
Ahmad Z Al Meslamani, Derar H Abdel-Qader
The Abuse and Misuse of Over-the-Counter Medicines During COVID-19. Hospital pharmacy 58 (5) (2023)
Ahmad Z Al Meslamani
Advancing towards a worldwide healthcare system in the post-COVID-19 era: benefits and barriers to international collaboration in healthcare. Journal of medical economics 26 (1) (2023)
Ahmad Z Al Meslamani, Anan S Jarab, Derar H Abdel-Qader, Osama Mohamed Ibrahim, Nadia Al Mazrouei
Adoption of electronic patient medication records in community pharmacies in the United Arab Emirates: A cross-sectional survey. Health information management : journal of the Health Information Management Association of Australia (2023)
Ahmad Z Al Meslamani
How does sleep influence asthma through immunity? Expert review of clinical immunology (2023)
Ahmad Z Al Meslamani
Underreporting of Adverse Drug Events: A Look into the Extent, Causes and Potential Solutions. Expert opinion on drug safety (2023)
Ahmad Z Al Meslamani
How AI is advancing asthma management? insights into economic and clinical aspects. Journal of medical economics (2023)
Ahmad Z Al Meslamani
Antibiotic resistance in low- and middle-income countries: current practices and its global implications. Expert review of anti-infective therapy (2023)
Ahmad Z Al Meslamani
Advancing towards a worldwide healthcare system in the post-COVID-19 era: benefits and barriers to international collaboration in healthcare. Journal of medical economics (2023)
Ahmad Z Al Meslamani
Beyond implementation: the long-term economic impact of AI in healthcare. Journal of medical economics (2023)
Ahmad Z Al Meslamani
Strategies for reducing chronic disease burden during pandemics. Current medical research and opinion (2023)
Nadia Al Mazrouei, Ahmad Z Al Meslamani, Rand Alajeel, Ghaid Alghadban, Neda Ansari, Samah Bahy Mohammed Ebaed, Rana M Ibrahim, Osama Mohamed Ibrahim
The patterns of herbal medicine use in the United Arab Emirates; A national study. Pharmacy practice 20 (3) (2022)
Nadia Al Mazrouei, Ahmad Z Al Meslamani, Rand Alajeel, Ghaid Alghadban, Neda Ansari, Samah Bahy Mohammed Ebaed, Rana M Ibrahim, Osama Mohamed Ibrahim
The patterns of herbal medicine use in the United Arab Emirates; A national study. Pharmacy practice 20 (3) (2022)
Derar H Abdel-Qader, Ahmad Z Al Meslamani, Abdullah Albassam, Nadia Al Mazrouei, Asma A El-Shara, Husam El Sharu, Samah Bahy Mohammed Ebaed, Osama Mohamed Ibrahim
Assessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies. Hospital pharmacy 57 (5) (2022)
Zelal Jaber Kharaba, Nour Sammani, Samar Ashour, Rose Ghemrawi, Ahmad Z Al Meslamani, Ahmad Al-Azayzih, Manal Ali Buabeid, Yassen Alfoteih
Caffeine Consumption among Various University Students in the UAE, Exploring the Frequencies, Different Sources and Reporting Adverse Effects and Withdrawal Symptoms. Journal of nutrition and metabolism 2022 (2022)
Zelal Jaber Kharaba, Sedq A Moutraji, Rama A Al Khawaldeh, Yassen Alfoteih, Ahmad Z Al Meslamani
What has changed in the pharmaceutical care after COVID-19: Pharmacists' perspective. Pharmacy practice 20 (2) (2022)
Ahmad Z Al Meslamani, Amira Bisher Kassem, Noha A El-Bassiouny, Osama Mohamed Ibrahim
An emergency plan for management of COVID-19 patients in rural areas. International journal of clinical practice 75 (10) (2021)
Derar H Abdel-Qader, Ahmad Z Al Meslamani, Nadia Al Mazrouei, Asma A El-Shara, Husam El Sharu, Eman Merghani Ali, Samah Bahy Mohammed Ebaed, Osama Mohamed Ibrahim
Virtual Coaching Delivered by Pharmacists to Prevent COVID-19 Transmission. Hospital pharmacy 57 (2) (2021)
Osama Mohamed Ibrahim, Noha A El-Bassiouny, Nadia Al Mazrouei, Ahmad Z Al Meslamani, Samah Bahy Mohammed Ebaed, Rana M Ibrahim, Amira Bisher Kassem
The effectiveness of pharmacist-based coaching in improving breast cancer-related health behaviors: A randomized controlled trial. Pharmacy practice 19 (4) (2021)
Osama M Ibrahim, Rana M Ibrahim, Ahmad Z Al Meslamani, Nadia Al Mazrouei
Role of telepharmacy in pharmacist counselling to coronavirus disease 2019 patients and medication dispensing errors. Journal of telemedicine and telecare (2020)
Osama Mohamed Ibrahim, Rana M Ibrahim, Ahmad Z Al Meslamani, Nadia Al Mazrouei
Dispensing errors in community pharmacies in the United Arab Emirates: investigating incidence, types, severity, and causes. Pharmacy practice 18 (4) (2020)
Derar H Abdel-Qader, Najlaa Saadi Ismael, Ahmad Z Al Meslamani, Abdullah Albassam, Asma' A El-Shara', Penny J Lewis, Salim Hamadi, Nadia Al Mazrouei
The Role of Clinical Pharmacy in Preventing Prescribing Errors in the Emergency Department of a Governmental Hospital in Jordan: A Pre-Post Study. Hospital pharmacy 56 (6) (2020)

Ahmad Z Al Meslamani.css-eqlu8i{font-size:small;padding-left:4px;} (Ahmad Z AlMeslamani)

Publication Activity (10 Years)

Top Topics

Top Venues

Ahmad Z Al Meslamani (Ahmad Z AlMeslamani)